Workflow
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
ADMA BiologicsADMA Biologics(US:ADMA) ZACKS·2025-11-06 22:30

Key Takeaways ADMA's Q3 EPS met estimates while revenues rose 12% year over year to 134.2million.Ascenivdroverecordutilizationandboostedgrossmarginto56.3134.2 million.Asceniv drove record utilization and boosted gross margin to 56.3% from 49.8%.ADMA raised 2025-26 revenue targets and advanced SG-001 toward potential FDA acceleration.ADMA Biologics (ADMA) reported third-quarter 2025 adjusted earnings per share (EPS) of 16 cents, which were in line with the Zacks Consensus Estimate. In the year-ago quarter, the company reported adjusted EPS of 15 cents. Revenues of 134.2 mil ...